Collins Property Group Full Year 2025 Earnings: EPS: R1.69 (vs R4.25 in FY 2024)
Revenue: R1.26b (up 7.2% from FY 2024).
Net income: R557.2m (down 51% from FY 2024).
Profit margin: 44% (down from 97% in FY 2024).
EPS: R1.69 (down from R4.25 in FY 2024).
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Collins Property Group shares are down 12% from a week ago.
It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Collins Property Group (at least 1 which doesn't sit too well with us), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
31 minutes ago
- Forbes
Buy LRCX Stock At $90?
CANADA - 2025/02/10: In this photo illustration, the Lam Research Corporation logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Lam Research (NASDAQ:LRCX) stock has experienced a notable increase this year, rising by 22% and significantly outperforming the S&P 500's modest gain of 2%. This remarkable performance can be attributed primarily to the company's solid quarterly results, fueled by strong foundry revenues and improving margins. Given this recent surge, the crucial question for investors is whether LRCX is still a compelling purchase. We believe it is. Despite its current price hovering around $90, we see little reason for worry regarding LRCX stock, particularly in light of its reasonable valuation. Our conclusion stems from a thorough analysis of Lam Research's operational performance in recent years, along with its current and historical financial health. We have assessed the company based on several core metrics: Growth, Profitability, Financial Stability, and Downturn Resilience. Our results show that Lam Research demonstrates exceptionally strong operating performance and financial stability, positioning it as an attractive investment option. However, for those investors who prefer lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and delivered returns exceeding 91% since its inception. Separately, see – What's Better – Circle Stock Or Bitcoin? When considering what you pay per dollar of sales or profit, LRCX stock appears slightly overvalued in relation to the wider market. Lam Research's Revenues have demonstrated significant growth over the past few years. Lam Research's profit margins are significantly higher than those of most companies in the Trefis coverage universe. Lam Research's balance sheet appears very robust. LRCX stock has underperformed compared to the benchmark S&P 500 index during some recent downturns. Concerned about how a market crash could affect LRCX stock? Our dashboard How Low Can Lam Research Stock Go In A Market Crash? provides an in-depth analysis of how the stock has fared during and after previous market crashes. In conclusion, Lam Research's performance across the discussed metrics is summarized as follows: Overall, Lam Research has demonstrated excellent performance across the critical metrics we evaluated. We believe this strong operational and financial health is not entirely reflected in the current moderate valuation of the stock, making LRCX an appealing investment. This further reinforces our belief that Lam Research is a solid investment choice. Although LRCX stock appears promising, investing in a single stock can entail risks. Conversely, the Trefis High Quality (HQ) Portfolio, comprising 30 stocks, has consistently outperformed the S&P 500 over the past 4-year period. Why is that the case? As a group, HQ Portfolio stocks yielded better returns with lower risk in comparison to the benchmark index; providing a smoother ride, as shown in HQ Portfolio performance metrics.
Bloomberg
33 minutes ago
- Bloomberg
BlackRock, Goldman Scale Up Tax Trades in $3 Trillion SMA Boom
This year's stock market turbulence has punished ordinary investors. But for the wealthy, it's opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. BlackRock Inc., Goldman Sachs Group Inc. and Morgan Stanley are among firms scaling up a strategy known as tax-loss harvesting, typically offered through customized portfolios called separately managed accounts. When markets drop, managers sell stocks trading below their purchase price to realize losses. Those losses offset gains elsewhere in a portfolio, reducing clients' tax liabilities while maintaining overall portfolio exposure.
Bloomberg
an hour ago
- Bloomberg
Stock Movers: JM Smucker, McDonalds, Novo Nordisk
On this episode of Stock Movers: - JM Smucker (SJM) shares fall after the company said it expects adjusted earnings of up to $9.50 a share, reduced by $1 a share due to higher coffee costs and US tariffs. The company raised coffee prices in May and plans to do so again in August, which is expected to hurt demand this year. -McDonalds (MCD) shares drop after Redburn Atlantic downgraded the company to a sell rating, citing concerns over shifting consumer patterns due to weight-loss drugs and inflation. The analyst estimates that the use of GLP-1 drugs like Ozempic could impact McDonald's revenue by $428 million annually, and potentially up to 10% or more over time. -Novo Nordisk (NOVOB) shares rise after a report that Parvus Asset Management has built a stake in the company. Parvus is interested in influencing the appointment of a new CEO, as Novo Nordisk is set to replace its current CEO Lars Fruergaard Jorgensen.
